drugset / Trial / NCT00879814

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

NCT00879814

Phase 1 Completed 48 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and tolerability of an investigational meningococcal B rLP2086 vaccine in healthy adults.

Timeline

Start
2009-04
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator rLP2086 Vaccine 60 ug Intramuscular
Comparator rLP2086 Vaccine 120 ug Intramuscular
Comparator rLP2086 Vaccine 200 ug Intramuscular